BioIVT Appoints Dr. Auro Nair as Chief Executive Officer

Audio By Carbonatix

WOODBURY, N.Y.--(BUSINESS WIRE)--Feb 2, 2026--

BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced the appointment of Dr. Auro Nair as the company’s Chief Executive Officer. Dr. Nair has served on BioIVT’s Board of Directors since June 2024.

“Dr. Nair brings deep life sciences experience, a drive for success, and exceptional commercial leadership. We are excited for BioIVT’s next phase of strategic growth and development under his guidance,” said Piyush Shukla, Chairman of the Board and Partner at Linden Capital Partners. “Auro’s leadership will help bolster our strong foundation and advance our mission of serving the global research community. I also want to thank outgoing CEO, Dr. Richard Haigh, for his many contributions at BioIVT and wish him the best in his future endeavors.”

Dr. Nair has more than 30 years of leadership experience in pharma services and life sciences. Most recently, he served as Executive Vice President of The Jackson Laboratory and President of its Mice, Clinical & Research Services business, where he led 16 years of sustained double-digit growth, supporting drug discovery and the development of precision medicine platforms. Dr. Nair has held leadership roles at Caliper Life Sciences and GlaxoSmithKline. He earned a bachelor’s degree in chemistry from Universiti Sains Malaysia, an MBA from Suffolk University, and a PhD in chemistry from the University of Oklahoma.

During this next stage of development under Dr. Nair’s leadership, BioIVT is looking forward to strengthening its focus on commercial growth and working even closer with its partners to deliver ever greater value to them and accelerate medical breakthroughs.

“I’m honored to lead BioIVT and energized to work alongside our talented team and partners as we together build the company’s next chapter with a rigorous focus on customer service and exceptional science,” said Dr. Nair. “BioIVT’s strong brand, 40-year history of excellence, and commitment to ethically sourced products and solutions of the highest quality, position us to play a critical role in advancing our mission of enabling medical breakthroughs and being a leader of biomedical innovation.”

About BioIVT
BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. We specialize in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE ®. For more information, please visit www.bioivt.com or follow us on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260202739527/en/

CONTACT: BioIVT Contact:Charlie Chungu, Vice President of Marketing,[email protected]

Media Contact: Paige Romine, PAN, 321-652-8370,[email protected]

KEYWORD: NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH GENERAL HEALTH RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: BioIVT

Copyright Business Wire 2026.

PUB: 02/02/2026 11:00 AM/DISC: 02/02/2026 11:00 AM

http://www.businesswire.com/news/home/20260202739527/en